Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:GNCA
- CUSIP: N/A
- Web: www.genocea.com
Capitalization:- Market Cap: $150.56 million
- Outstanding Shares: 28,624,000
Average Prices:- 50 Day Moving Avg: $4.77
- 200 Day Moving Avg: $5.55
- 52 Week Range: $3.28 - $7.29
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.27
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.67 per share
- Price / Book: 7.85
Profitability:- EBIDTA: ($54,720,000.00)
- Return on Equity: -146.46%
- Return on Assets: -92.29%
Debt:- Debt-to-Equity Ratio: 0.56%
- Current Ratio: 2.97%
- Quick Ratio: 2.97%
Misc:- Average Volume: 548,736 shs.
- Beta: 2.29
- Short Ratio: 4.44
Frequently Asked Questions for Genocea Biosciences (NASDAQ:GNCA)
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.08. View Genocea Biosciences' Earnings History.
When will Genocea Biosciences make its next earnings announcement?
Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?
4 brokerages have issued 12 month price objectives for Genocea Biosciences' stock. Their predictions range from $12.00 to $40.00. On average, they expect Genocea Biosciences' stock price to reach $21.75 in the next twelve months. View Analyst Ratings for Genocea Biosciences.
What are analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (8/17/2017)
- 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Protagonist Therapeutics (PTGX), Codexis (CDXS), Nabriva Therapeutics AG (NBRV), Curis (CRIS), Organovo Holdings (ONVO), Organovo Holdings (ONVO), Horizon Discovery Group PLC (HZD), Chromadex Corp (CDXC), Advaxis (ADXS), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Pluristem Therapeutics (PSTI), Regulus Therapeutics (RGLS), GTx (GTXI) and Novelion Therapeutics (NVLN).
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Katrine S. Bosley, Chairman of the Board
- William D. Clark, President, Chief Executive Officer, Director
- Jonathan M. Poole, Chief Financial Officer
- John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences
- Jessica Baker Flechtner Ph.D., Chief Scientific Officer
- Seth V. Hetherington M.D., Chief Medical Officer
- Eric S. Hoffman Ph.D., Chief Business Officer
- Ronald Harold Wilfred Cooper, Director
- George Siber M.D., Director
- Kenneth M. Bate, Independent Director
Who owns Genocea Biosciences stock?
Genocea Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Franklin Resources Inc. (10.51%), Northpointe Capital LLC (4.69%), Vanguard Group Inc. (3.01%), AXA (2.06%) and Sphera Funds Management LTD. (1.72%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.
Who sold Genocea Biosciences stock? Who is selling Genocea Biosciences stock?
Who bought Genocea Biosciences stock? Who is buying Genocea Biosciences stock?
Genocea Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Northpointe Capital LLC, Vanguard Group Inc., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.
How do I buy Genocea Biosciences stock?
Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of Genocea Biosciences stock can currently be purchased for approximately $5.26.
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Genocea Biosciences (NASDAQ:GNCA)Earnings History by Quarter for Genocea Biosciences (NASDAQ GNCA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | ($0.51) | | | | | N/A |  |
| 8/9/2017 | Q2 2017 | ($0.46) | ($0.54) | | | View | N/A | |
| 5/4/2017 | 3/31/2017 | ($0.54) | ($0.48) | | | View | Listen | |
| 2/16/2017 | Q416 | ($0.45) | ($0.56) | | | View | N/A | |
| 11/3/2016 | Q316 | ($0.44) | ($0.45) | | | View | N/A | |
| 8/4/2016 | Q216 | ($0.44) | ($0.39) | | | View | N/A | |
| 5/5/2016 | Q116 | ($0.42) | ($0.35) | | $0.24 million | View | N/A | |
| 2/11/2016 | Q415 | ($0.40) | ($0.37) | | $0.22 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.43) | ($0.37) | | $0.21 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.51) | ($0.43) | | $0.12 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.57) | ($0.64) | | $0.12 million | View | Listen | |
| 2/12/2015 | Q414 | ($0.53) | ($0.66) | | $0.31 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.43) | ($0.53) | | | View | N/A | |
| 8/6/2014 | Q2 | ($0.42) | ($0.41) | | | View | N/A | |
| 5/6/2014 | Q114 | ($0.60) | ($0.76) | $0.26 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)Current Year EPS Consensus Estimate: $-1.98 EPS
Next Year EPS Consensus Estimate: $-1.61 EPS
Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Genocea Biosciences (NASDAQ:GNCA)Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 59.25%
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/24/2017 | Jonathan Poole | CFO | Sell | 45,000 | $6.00 | $270,000.00 | |
| 11/8/2016 | Eric S. Hoffman | Insider | Buy | 7,000 | $3.49 | $24,430.00 | |
| 11/7/2016 | Jonathan Poole | CFO | Buy | 7,000 | $3.34 | $23,380.00 | |
| 11/7/2016 | William D. Clark | Insider | Buy | 2,800 | $3.49 | $9,772.00 | |
| 5/9/2016 | Jonathan Poole | CFO | Buy | 4,000 | $3.88 | $15,520.00 | |
| 12/16/2015 | William D Clark | CEO | Buy | 3,800 | $6.45 | $24,510.00 | |
| 9/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $11.35 | $25,299.15 | |
| 6/19/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 30,004 | $13.04 | $391,252.16 | |
| 6/17/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 10,618 | $13.01 | $138,140.18 | |
| 6/16/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 46,000 | $13.24 | $609,040.00 | |
| 6/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.52 | $23,449.08 | |
| 5/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.21 | $22,758.09 | |
| 4/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,283 | $11.77 | $26,870.91 | |
| 3/17/2015 | Stephen J Hoffman | Director | Buy | 700,000 | $8.25 | $5,775,000.00 | |
| 2/2/2015 | Jessica Baker Flechtner | VP | Sell | 4,699 | $8.50 | $39,941.50 | |
| 9/12/2014 | Jessica Baker Flechtner | VP | Sell | 6,435 | $12.00 | $77,220.00 | |
| 9/11/2014 | Paul Giannasca | VP | Sell | 4,071 | $11.84 | $48,200.64 | |
| 9/10/2014 | Paul Giannasca | VP | Sell | 834 | $12.35 | $10,299.90 | |
| 9/9/2014 | Paul Giannasca | VP | Sell | 2,455 | $12.43 | $30,515.65 | |
| 9/8/2014 | Paul Giannasca | VP | Sell | 2,970 | $12.80 | $38,016.00 | |
| 8/29/2014 | Paul Giannasca | VP | Sell | 6,760 | $12.50 | $84,500.00 | |
| 8/14/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 9,660 | $13.01 | $125,676.60 | |
| 8/12/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 63,794 | $13.28 | $847,184.32 | |
| 2/10/2014 | Plc Glaxosmithkline | Insider | Buy | 143,773 | $12.00 | $1,725,276.00 | |
| 2/10/2014 | Polaris Venture Management Co. | Major Shareholder | Buy | 232,820 | $12.00 | $2,793,840.00 | |
| 2/10/2014 | Stephen J Hoffman | Director | Buy | 250,931 | $12.00 | $3,011,172.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Genocea Biosciences (NASDAQ:GNCA)
Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Brokerages Expect Genocea Biosciences, Inc. (GNCA) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - September 11 at 10:34 AM |
| Head to Head Review: Genocea Biosciences (GNCA) and Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - September 6 at 12:16 AM |
| Genocea Biosciences, Inc. (GNCA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 9:12 AM |
| Brokerages Expect Genocea Biosciences, Inc. (GNCA) to Post -$0.51 Earnings Per Share
www.americanbankingnews.com - August 23 at 10:20 PM |
| Zacks Investment Research Upgrades Genocea Biosciences, Inc. (GNCA) to Hold
www.americanbankingnews.com - August 17 at 10:40 PM |
| Genocea Biosciences, Inc. (GNCA) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 11 at 10:58 PM |
 | Genocea Biosciences Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 7:19 PM |
| Genocea Biosciences reports 2Q loss
finance.yahoo.com - August 9 at 7:19 PM |
| Genocea Biosciences, Inc. (GNCA) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 9 at 5:32 PM |
| Analysts Anticipate Genocea Biosciences, Inc. (GNCA) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - August 5 at 2:22 PM |
| Genocea Biosciences, Inc. (NASDAQ:GNCA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 5 at 8:44 AM |
 | Genocea Biosciences (GNCA) Announces Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
www.streetinsider.com - July 27 at 12:48 AM |
 | Genocea Biosciences's (GNCA) Conference Call On Positive GEN-003 Phase 2b Results - Slideshow
seekingalpha.com - July 27 at 12:48 AM |
| Genocea Biosciences' (NASDAQ:GNCA) Outperform Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - July 25 at 11:10 AM |
| Genocea Biosciences, Inc. (GNCA) Receives "Overweight" Rating from Piper Jaffray Companies
www.americanbankingnews.com - July 25 at 11:10 AM |
 | 18 Biggest Mid-Day Gainers For Monday | Benzinga - Benzinga
www.benzinga.com - July 24 at 8:54 PM |
 | Pre-Market Most Active for Jul 24, 2017 : WBMD, NDRM, QQQ ... - Nasdaq
www.nasdaq.com - July 24 at 8:54 PM |
| Genocea Biosciences (GNCA) Announces Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes - StreetInsider.com
www.streetinsider.com - July 24 at 8:54 PM |
| Genocea Biosciences Inc (GNCA): This Analyst Turns Bullish, Sets $12 Target Price
finance.yahoo.com - July 24 at 8:54 PM |
| Cowen Sings the Praises of Genocea Biosciences Inc (GNCA) Following Positive GEN-003 Phase 2b Data
finance.yahoo.com - July 24 at 8:54 PM |
| Genocea Biosciences, Inc. (GNCA) CFO Sells $270,000.00 in Stock
www.americanbankingnews.com - July 24 at 7:29 PM |
| Genocea Biosciences, Inc. (GNCA) Upgraded to "Buy" at Needham & Company LLC
www.americanbankingnews.com - July 24 at 4:50 PM |
 | Genocea Reports 12-Month Phase 2b Data For GEN-003 In Genital Herpes
www.rttnews.com - July 24 at 8:56 AM |
| Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
feeds.benzinga.com - July 24 at 7:38 AM |
| Genocea Biosciences, Inc. (NASDAQ:GNCA) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 11:08 PM |
| Genocea Biosciences, Inc. (GNCA) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - July 14 at 11:32 AM |
| Genocea Biosciences, Inc. (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:26 AM |
| Genocea Added to Russell 3000® and Russell 2000® Indices
finance.yahoo.com - June 26 at 9:32 AM |
| Brokerages Anticipate Genocea Biosciences, Inc. (GNCA) Will Announce Earnings of -$0.46 Per Share
www.americanbankingnews.com - June 20 at 8:16 AM |
| Genocea Biosciences, Inc. (GNCA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 16 at 8:16 AM |
| Genocea Biosciences Inc (GNCA) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - June 6 at 11:02 PM |
| Genocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 5 at 11:16 PM |
| Genocea: Investment Update On ~$6 Biotech 'Busted IPO ... - Seeking Alpha
seekingalpha.com - June 1 at 3:28 AM |
| Genocea Biosciences Inc (GNCA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 31 at 11:24 PM |
| Genocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 31 at 12:02 AM |
| Genocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 22 at 7:56 AM |
| Genocea Biosciences Inc (GNCA) Short Interest Update
www.americanbankingnews.com - May 16 at 7:20 AM |
| Genocea Biosciences Inc (GNCA) Issues Earnings Results
www.americanbankingnews.com - May 8 at 4:40 PM |
| Genocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes
finance.yahoo.com - May 4 at 12:07 PM |
| Investor Network: Genocea Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:07 PM |
 | Genocea Biosciences reports 1Q loss
marketbeat.com - May 4 at 9:29 AM |
| Zacks: Brokerages Expect Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - May 2 at 12:06 AM |
| Genocea Biosciences (GNCA) Earning Somewhat Critical Media Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 8:02 AM |
| Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET
finance.yahoo.com - April 27 at 8:05 AM |
| Somewhat Positive Press Coverage Extremely Likely to Impact Genocea Biosciences (GNCA) Stock Price
www.americanbankingnews.com - April 26 at 8:44 AM |
| Genocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 11:05 AM |
| Genocea Biosciences (GNCA) Receives Media Impact Score of -0.22
www.americanbankingnews.com - April 20 at 8:53 AM |
| Genocea Biosciences (GNCA) Receiving Very Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 8:58 AM |
| Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes
finance.yahoo.com - April 11 at 12:15 PM |
| Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 10 at 8:30 PM |
Genocea Biosciences (GNCA) Chart for Tuesday, September, 19, 2017
